ArticleFuture oncology (London, England)2024
What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?
Burak Bilgin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.